Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to new ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock ...

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...

Boy George showed off his new look as he attended the opening of John Proctor is the Villain, which was held at the Booth Theatre in Midtown Manhattan on Monday.

Skye Bioscience (SKYE) announced new preclinical data for its novel CB1 antibody, nimacimab. In a murine diet-induced obesity model, after 25 ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek more accessible treatment options ...

Groundbreaking study shows combining resistance training with protein-rich diet helps to preserve muscle mass while using GLP-1 weight loss medications.

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in ...